Vertex: A Good Bet, If You’ve a Mind for Patience

by

Now, I’ve seen a good many companies come and go in my time, like fireflies on a summer night – bright for a spell, then vanished into the dark. But this Vertex Pharmaceuticals, it’s a curious case. They’ve built themselves a little kingdom in the realm of cystic fibrosis, a nasty ailment if ever there was one, and for that, they deserve a nod. They ain’t reinvented the wheel, mind you, but they’ve greased it right smartly, and that’s brought them a goodly sum over the last decade. Seems folks are willing to pay a pretty penny when their breathin’s at stake.

They’ve been dabblin’ in other potions and elixirs of late, too – gene editing and pain relief, among other things. Approval for Casgevy and Journavx, they call it. Sounds like somethin’ a wizard might concoct. But don’t let the fancy names fool ya, the real gold, as always, lies in what they do best.

Folks are askin’ me why I’d buy this stock and hold onto it like a miser to his hoard. And I’ll tell ya, it ain’t for any grand visions of savin’ the world, though they’ll surely tell ya that’s what they’re doin’. No sir. It’s a simpler reason than that, and a more reliable one, I reckon.

Expandin’ the Territory

Now, this company, they had a bit of a wobble a while back. Folks were frettin’ they couldn’t spread their wings beyond this CF business. A few experiments went south, and the stock took a bit of a tumble. But they righted the ship, and the market, bless its fickle heart, rewarded ’em for it. Shares climbed somethin’ fierce over the last three years, more than 60 percent, they say. A testament to the power of a good story, and a healthy dose of optimism.

Loading widget...

But here’s the rub. I ain’t buyin’ this stock for their dabblin’s in new fields. I’m holdin’ onto it for what they already do well. Their strength in CF, that’s the real treasure. They claim they’ve got patents and protections that’ll keep ’em ahead of the game for years to come, well into the 2030s. Sounds like a tall tale, but they’ve earned the right to spin one, I suppose.

And their latest potion, Alyftrek, it’s even better than their blockbuster, Trikafta, they say. Now, I’m no doctor, but I reckon a drug that works better than the last one is a good sign. Both of ’em are bringin’ in the dollars, and Vertex ain’t one to rest on its laurels. They’re always lookin’ for the next edge.

Reachin’ Most of the Folks

Alyftrek and Trikafta, they can help about 90 percent of those afflicted with CF. Now, that’s a respectable number, considerin’ how complicated these ailments can be. It seems this CF is tied to specific genetic quirks, makin’ it tricky to find a one-size-fits-all cure. But Vertex is workin’ on it, partnerin’ with Moderna, of all folks, to develop a new potion, VX-522. They’re in the early stages of testin’, but they expect to have some results this year.

This CF business already brings in a mighty sum for Vertex – billions, they claim. And with new potions on the horizon, and those patents protectin’ their territory, it looks like this golden goose will keep layin’ eggs for a good long while. That’s why I’d buy this stock, and hold onto it tighter than a prospector to his gold. It ain’t a guarantee, mind you – nothin’ ever is – but it’s as close to a sure thing as you’re likely to find in this world.

Read More

2026-02-10 21:23